These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23435876)

  • 1. A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer.
    Ramnath N; Daignault-Newton S; Dy GK; Muindi JR; Adjei A; Elingrod VL; Kalemkerian GP; Cease KB; Stella PJ; Brenner DE; Troeschel S; Johnson CS; Trump DL
    Cancer Chemother Pharmacol; 2013 May; 71(5):1173-82. PubMed ID: 23435876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
    Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
    Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: results of a phase II study.
    Firvida JL; Amenedo M; Rodríguez R; González A; Salgado M; Ramos M; Losada G
    Invest New Drugs; 2004 Nov; 22(4):481-7. PubMed ID: 15292719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study.
    Douillard JY; Gervais R; Dabouis G; Le Groumellec A; D'Arlhac M; Spaeth D; Coudert B; Caillaud D; Monnier A; Clary C; Maury B; Mornet M; Rivière A; Clouet P; Couteau C
    Ann Oncol; 2005 Jan; 16(1):81-9. PubMed ID: 15598943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
    Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
    J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y; Ohsugi S; Natsuhara A; Tsubokura T; Harada H; Ueda M; Arimoto T; Hara H; Yamada T; Takesako T; Kohno K; Hosogi S; Nakanishi M; Marunaka Y; Nishimura T
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):735-41. PubMed ID: 16565832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
    Georgoulias V; Androulakis N; Dimopoulos AM; Kourousis C; Kakolyris S; Papadakis E; Apostolopoulou F; Papadimitriou C; Vossos A; Agelidou M; Heras P; Tzannes S; Vlachonicolis J; Mavromanolakis E; Hatzidaki D
    Ann Oncol; 1998 Mar; 9(3):331-4. PubMed ID: 9602269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study.
    Mudad R; Ramsey M; Kovitz K; Curiel TJ; Hartz R; Nedzi LL; Weiner RS; Zakris EL
    Lung Cancer; 2003 Feb; 39(2):173-7. PubMed ID: 12581570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.
    Otterson GA; Villalona-Calero MA; Hicks W; Pan X; Ellerton JA; Gettinger SN; Murren JR
    Clin Cancer Res; 2010 Apr; 16(8):2466-73. PubMed ID: 20371682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small cell lung cancer.
    Koizumi T; Tsunoda T; Fujimoto K; Nomura H; Hirai K; Koyama S; Okada K; Kubo K
    Lung Cancer; 2001 Oct; 34(1):125-31. PubMed ID: 11557122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer.
    Zalcberg J; Millward M; Bishop J; McKeage M; Zimet A; Toner G; Friedlander M; Barter C; Rischin D; Loret C; James R; Bougan N; Berille J
    J Clin Oncol; 1998 May; 16(5):1948-53. PubMed ID: 9586914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016.
    Ikeda S; Kato T; Ogura T; Sekine A; Oda T; Masuda N; Igawa S; Katono K; Otani S; Yamada K; Saito H; Kondo T; Hosomi Y; Nakahara Y; Nishikawa M; Utumi K; Misumi Y; Yamanaka T; Sakamaki K; Okamoto H
    BMC Cancer; 2018 Mar; 18(1):241. PubMed ID: 29499653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.
    Niho S; Ohe Y; Kakinuma R; Kubota K; Matsumoto T; Ohmatsu H; Goto K; Nishiwaki Y
    Lung Cancer; 2002 Feb; 35(2):209-14. PubMed ID: 11804695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of weekly docetaxel and cisplatin in advanced non-small cell lung cancer.
    Sato K; Tsuchiya S; Minato K; Takei Y; Watanabe S; Saitoh R; Mori M
    Lung Cancer; 2001 Jul; 33(1):69-73. PubMed ID: 11429197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
    Kentepozidis N; Kotsakis A; Soultati A; Agelaki S; Christophylakis Ch; Agelidou M; Chelis L; Papakotoulas P; Vamvakas L; Zafiriou Z; Samonis G; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):605-12. PubMed ID: 23338050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.